基本介紹
- 中文名：周旭宇
- 國籍：中國
- 民族：漢族
- 出生日期：1972年
- 性別：男
人物經歷,研究領域,代表作品,
人物經歷
1989年9月-1993年7月山東大學生命科學院微生物系微生物學專業，獲理學學士學位
1993年9月-1996年7月 山東農業大學植保系植物病理專業，獲理學碩士學位
1996年12月-1997年3月日本大阪大學，大學院醫學系研究科病理專業，腫瘤發生學研究室，進修生
1997年4月- 2001年3月 日本大阪大學，大學院醫學系研究科病理專業，腫瘤發生學研究室，獲醫學博士學位
2001年4月-2002年3月 日本大阪大學， 大學院醫學系研究科病理專業，腫瘤發生學研究室，交流學者
2002年4月-2003年9月 日本大阪大學醫學系研究科病理專業，腫瘤發生學研究室，研究助理
2003年10月-2009年9月 美國加州大學舊金山分校糖尿病研究中心，免疫學，博士後
1993年9月-1996年7月 山東農業大學植保系植物病理專業，獲理學碩士學位
1996年12月-1997年3月日本大阪大學，大學院醫學系研究科病理專業，腫瘤發生學研究室，進修生
1997年4月- 2001年3月 日本大阪大學，大學院醫學系研究科病理專業，腫瘤發生學研究室，獲醫學博士學位
2001年4月-2002年3月 日本大阪大學， 大學院醫學系研究科病理專業，腫瘤發生學研究室，交流學者
2002年4月-2003年9月 日本大阪大學醫學系研究科病理專業，腫瘤發生學研究室，研究助理
2003年10月-2009年9月 美國加州大學舊金山分校糖尿病研究中心，免疫學，博士後
研究領域
周旭宇1.調節性T細胞抑制機理。
2.調節性T細胞自身穩定性的調控機制。
代表作品
1. Tomura M, Zhou XY, Maruo S, Ahn HJ, Hamaoka T, Okamura H, Nakanishi K, Tanimoto T, Kurimoto M, Fujiwara H. A critical role for IL-18 in the proliferation and activation of NK1.1+ CD3- cells. J Immunol. 1998;160:4738-46.
2. Tomura M, Maruo S, Mu J, Zhou XY, Ahn HJ, Hamaoka T, Okamura H, Nakanishi K, Clark S, Kurimoto M, Fujiwara H. Differential capacities of CD4+, CD8+, and CD4-CD8- T cell subsets to express IL-18 receptor and produce IFN-gamma in response to IL-18. J Immunol. 1998;160:3759-65.
3. Yashiro-Ohtani Y, Zhou XY, Toyo-Oka K, Tai XG, Park CS, Hamaoka T, Abe R, Miyake K, Fujiwara H. Non-CD28 costimulatory molecules present in T cell rafts induce T cell costimulation by enhancing the association of TCR with rafts. J Immunol. 2000;164:1251-9.
4. Zhou XY, Yashiro-Ohtani Y, Toyo-Oka K, Park CS, Tai XG, Hamaoka T, Fujiwara H. CD5 costimulation up-regulates the signaling to extracellular signal-regulated kinase activation in CD4+CD8+ thymocytes and supports their differentiation to the CD4 lineage. J Immunol. 2000;164:1260-8.
5. Park CS, Yang YF, Zhou XY, Toyooka K, Yashiro-Ohtani Y, Park WR, Tomura M, Tai XG, Hamaoka T, Fujiwara H. Reversible CD8 expression induced by common cytokine receptor gamma chain-dependent cytokines in a cloned CD4(+) T(h)1 cell line. Int Immunol. 2002;14:259-66.
6. Zhou XY, Yashiro-Ohtani Y, Nakahira M, Park WR, Abe R, Hamaoka T, Naramura M, Gu H, Fujiwara H. Molecular mechanisms underlying differential contribution of CD28 versus non-CD28 costimulatory molecules to IL-2 promoter activation. J Immunol. 2002;168:3847-54.
7. Gao P, Zhou XY, Yashiro-Ohtani Y, Yang YF, Sugimoto N, Ono S, Nakanishi T, Obika S, Imanishi T, Egawa T, Nagasawa T, Fujiwara H, Hamaoka T. The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3. J Leukoc Biol. 2003;73:273-80.
8. Park WR, Nakahira M, Sugimoto N, Bian Y, Yashiro-Ohtani Y, Zhou XY, Yang YF, Hamaoka T, Fujiwara H. A mechanism underlying STAT4-mediated up-regulation of IFN-gamma induction inTCR-triggered T cells. Int Immunol. 2004;16:295-302.
9. Takeuchi N, Hiraoka S, Zhou XY, Nagafuku M, Ono S, Tsujimura T, Nakazawa M, Yura Y, Hamaoka T, Fujiwara H. Anti-HER-2/neu immune responses are induced before the development of clinical tumors but declined following tumorigenesis in HER-2/neu transgenic mice. Cancer Res. 2004;64:7588-95.
10. Yamaguchi N, Hiraoka S, Mukai T, Takeuchi N, Zhou XY, Ono S, Kogo M, Dunussi-Joannopoulos K, Ling V, Wolf S, Fujiwara H. Induction of tumor regression by administration of B7-Ig fusion proteins: mediation by type 2 CD8+ T cells and dependence on IL-4 production. J Immunol. 2004;172:1347-54.
11. Bian Y, Hiraoka S, Tomura M, Zhou XY, Yashiro-Ohtani Y, Mori Y, Shimizu J, Ono S, Dunussi-Joannopoulos K, Wolf S, Fujiwara H. The capacity of the natural ligands for CD28 to drive IL-4 expression in naive and antigen-primed CD4+ and CD8+ T cells. Int Immunol. 2005;17:73-83.
12. Earle KE, Tang Q, Zhou X, Liu W, Zhu S, Bonyhadi ML, Bluestone JA. In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation. Clin Immunol. 2005;115:3-9.
13. Morimoto Y, Bian Y, Gao P, Yashiro-Ohtani Y, Zhou XY, Ono S, Nakahara H, Kogo M, Hamaoka T, Fujiwara H. Induction of surface CCR4 and its functionality in mouse Th2 cells is regulated differently during Th2 development. J Leukoc Biol. 2005;78:753-61.
14. Liu W, Putnam AL, Zhou X, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Groth B, Clayberger C, Soper D, Ziegler S, Bluestone JA. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Tregs. J. Exp.Med. 2006 Jul 10;203(7):1701-11.
15. Gardner JM, Devoss JJ, Friedman RS, Wong DJ, Tan YX, Zhou X, Johannes KP, Su MA, Chang HY, Krummel MF, Anderson MS. Deletional tolerance mediated by extrathymic Aire-expressing cells.Science. 2008 Aug 8;321(5890):843-7.
16. Zhou X, Jeker LT, Fife BT, Zhu S, Anderson MS, McManus MT, Bluestone JA. Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med. 2008 Sep 1;205(9):1983-91. Epub 2008 Aug 25.
17. Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA. Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol. 2009 Jun;21(3):281-5. Epub 2009 Jun 6. Review.
18. Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martínez-Llordella M, Ashby M, Nakayama M, Rosenthal W, Bluestone JA. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol. 2009 Sep;10(9):1000-7. Epub 2009 Jul 26.
2. Tomura M, Maruo S, Mu J, Zhou XY, Ahn HJ, Hamaoka T, Okamura H, Nakanishi K, Clark S, Kurimoto M, Fujiwara H. Differential capacities of CD4+, CD8+, and CD4-CD8- T cell subsets to express IL-18 receptor and produce IFN-gamma in response to IL-18. J Immunol. 1998;160:3759-65.
3. Yashiro-Ohtani Y, Zhou XY, Toyo-Oka K, Tai XG, Park CS, Hamaoka T, Abe R, Miyake K, Fujiwara H. Non-CD28 costimulatory molecules present in T cell rafts induce T cell costimulation by enhancing the association of TCR with rafts. J Immunol. 2000;164:1251-9.
4. Zhou XY, Yashiro-Ohtani Y, Toyo-Oka K, Park CS, Tai XG, Hamaoka T, Fujiwara H. CD5 costimulation up-regulates the signaling to extracellular signal-regulated kinase activation in CD4+CD8+ thymocytes and supports their differentiation to the CD4 lineage. J Immunol. 2000;164:1260-8.
5. Park CS, Yang YF, Zhou XY, Toyooka K, Yashiro-Ohtani Y, Park WR, Tomura M, Tai XG, Hamaoka T, Fujiwara H. Reversible CD8 expression induced by common cytokine receptor gamma chain-dependent cytokines in a cloned CD4(+) T(h)1 cell line. Int Immunol. 2002;14:259-66.
6. Zhou XY, Yashiro-Ohtani Y, Nakahira M, Park WR, Abe R, Hamaoka T, Naramura M, Gu H, Fujiwara H. Molecular mechanisms underlying differential contribution of CD28 versus non-CD28 costimulatory molecules to IL-2 promoter activation. J Immunol. 2002;168:3847-54.
7. Gao P, Zhou XY, Yashiro-Ohtani Y, Yang YF, Sugimoto N, Ono S, Nakanishi T, Obika S, Imanishi T, Egawa T, Nagasawa T, Fujiwara H, Hamaoka T. The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3. J Leukoc Biol. 2003;73:273-80.
8. Park WR, Nakahira M, Sugimoto N, Bian Y, Yashiro-Ohtani Y, Zhou XY, Yang YF, Hamaoka T, Fujiwara H. A mechanism underlying STAT4-mediated up-regulation of IFN-gamma induction inTCR-triggered T cells. Int Immunol. 2004;16:295-302.
9. Takeuchi N, Hiraoka S, Zhou XY, Nagafuku M, Ono S, Tsujimura T, Nakazawa M, Yura Y, Hamaoka T, Fujiwara H. Anti-HER-2/neu immune responses are induced before the development of clinical tumors but declined following tumorigenesis in HER-2/neu transgenic mice. Cancer Res. 2004;64:7588-95.
10. Yamaguchi N, Hiraoka S, Mukai T, Takeuchi N, Zhou XY, Ono S, Kogo M, Dunussi-Joannopoulos K, Ling V, Wolf S, Fujiwara H. Induction of tumor regression by administration of B7-Ig fusion proteins: mediation by type 2 CD8+ T cells and dependence on IL-4 production. J Immunol. 2004;172:1347-54.
11. Bian Y, Hiraoka S, Tomura M, Zhou XY, Yashiro-Ohtani Y, Mori Y, Shimizu J, Ono S, Dunussi-Joannopoulos K, Wolf S, Fujiwara H. The capacity of the natural ligands for CD28 to drive IL-4 expression in naive and antigen-primed CD4+ and CD8+ T cells. Int Immunol. 2005;17:73-83.
12. Earle KE, Tang Q, Zhou X, Liu W, Zhu S, Bonyhadi ML, Bluestone JA. In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation. Clin Immunol. 2005;115:3-9.
13. Morimoto Y, Bian Y, Gao P, Yashiro-Ohtani Y, Zhou XY, Ono S, Nakahara H, Kogo M, Hamaoka T, Fujiwara H. Induction of surface CCR4 and its functionality in mouse Th2 cells is regulated differently during Th2 development. J Leukoc Biol. 2005;78:753-61.
14. Liu W, Putnam AL, Zhou X, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Groth B, Clayberger C, Soper D, Ziegler S, Bluestone JA. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Tregs. J. Exp.Med. 2006 Jul 10;203(7):1701-11.
15. Gardner JM, Devoss JJ, Friedman RS, Wong DJ, Tan YX, Zhou X, Johannes KP, Su MA, Chang HY, Krummel MF, Anderson MS. Deletional tolerance mediated by extrathymic Aire-expressing cells.Science. 2008 Aug 8;321(5890):843-7.
16. Zhou X, Jeker LT, Fife BT, Zhu S, Anderson MS, McManus MT, Bluestone JA. Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med. 2008 Sep 1;205(9):1983-91. Epub 2008 Aug 25.
17. Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA. Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol. 2009 Jun;21(3):281-5. Epub 2009 Jun 6. Review.
18. Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martínez-Llordella M, Ashby M, Nakayama M, Rosenthal W, Bluestone JA. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol. 2009 Sep;10(9):1000-7. Epub 2009 Jul 26.
